PURE Bioscience to Host Year End Results Conference Call October 24, 2013
New Management Team Discussion of Refocused Business Strategy
SAN DIEGO, CA -- (Marketwired) -- 10/22/13 -- PURE Bioscience, Inc.
(OTCQB: PURE), creator of the patented silver dihydrogen citrate
(SDC) antimicrobial, today announced that the Company will host an
investor conference call on Thursday, October 24, 2013 at 2:00 PM
Pacific Time (5:00 pm Eastern Time). In addition to reviewing fiscal
year end 2013 financial results, the purpose of this call is to:
-- Introduce the new management team,
-- Outline the Company's refocused business strategy in the food safety
-- Discuss steps being taken to restore PURE's financial condition.
PURE intends to file its Form 10-K on the October 24th after the close
of the stock market.
The Participant Dial-In Number for the conference call is
1-412-902-6720. Participants should dial in to the call at least five
minutes before 2:00 pm PDT (5:00 pm EDT) on October 24, 2013. The
call can also be accessed "live" online at
A replay of the webcast will be available at
http://public.viavid.com/index.php?id=106520 as well as on the
Company's website (www.purebio.com). Also, a replay of the conference
call will be available by dialing 1-877-870-5176 (international
participants dial 1-858-384-5517) starting October 24, 2013, at 8:00
PM Eastern Time through December 8, 2013 at 11:59 pm Eastern Time.
Please use PIN Number 91024.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing
our proprietary antimicrobial products that provide solutions to the
health and environmental challenges of pathogen and hygienic control.
Our technology platform is based on patented stabilized ionic silver,
and our initial products contain silver dihydrogen citrate, or SDC.
SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers
24-hour residual protection and formulates well with other compounds.
As a platform technology, SDC is distinguished from competitors in
the marketplace because of its superior efficacy, reduced toxicity
and the inability of bacteria to form a resistance to it. PURE is
headquartered in El Cajon, California (San Diego metropolitan area).
Additional information on PURE is available at www.purebio.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "expect," "intend," "project" or similar expressions.
These statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's cash
position and liquidity requirements, the Company's failure to
implement or otherwise achieve the benefits of its proposed business
initiatives and plans, acceptance of the Company's current and future
products and services in the marketplace, the ability of the Company
to develop effective new products and receive regulatory approvals of
such products, competitive factors, dependence upon third-party
vendors, and other risks detailed in the Company's periodic report
filings with the Securities and Exchange Commission. You should not
place undue reliance on these forward-looking statements. By making
these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes after
the date of this release.
Redwood Investment Group
Terri MacInnis, Director of IR
Bibicoff + MacInnis, Inc.
Peter C. Wulff, CFO & COO
PURE Bioscience, Inc.
Press spacebar to pause and continue. Press esc to stop.